Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5554736 | 0.91 | USP2 (0.44) | CYP2D6USP2SMN1; SMN2GPR119HPGD | |
| SCHEMBL10201505 | 0.91 | CYP11B2 (0.47) | CYP2D6USP2SMN1; SMN2GPR119CYP11B2 | |
| SCHEMBL17946237 | 0.89 | ACACB (0.42) | CYP2D6USP2SMN1; SMN2HPGDCYP11B2 | |
| SCHEMBL31042683 | 0.88 | CYP2D6 (0.44) | CYP2D6USP2SMN1; SMN2GPR119TSHR | |
| SCHEMBL20353659 | 0.86 | CYP2D6 (0.48) | CYP2D6USP2SMN1; SMN2GPR119TSHR | |
| SCHEMBL1306945 | 0.85 | USP2 (0.53) | USP2SMN1; SMN2HPGDEPHX2CHRM2 | |
| SCHEMBL30049604 | 0.85 | CYP2D6 (0.44) | CYP2D6USP2SMN1; SMN2GPR119TSHR | |
| SCHEMBL346995 | 0.85 | USP2 (0.56) | CYP2D6USP2SMN1; SMN2GPR119HPGD | |
| SCHEMBL10263386 | 0.83 | CYP2D6 (0.46) | CYP2D6USP2SMN1; SMN2GPR119TSHR | |
| SCHEMBL26148187 | 0.83 | CYP2D6 (0.46) | CYP2D6USP2SMN1; SMN2GPR119TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9993554-B2 | Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2018-06-12 | — | — | US | disclosed |
| US-9993554-B2 | Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2018-06-12 | — | — | US | disclosed |
| US-8778935-B2 | Imidazopyrazines for use as kinase inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-07-15 | — | — | US | disclosed |
| US-20140154232-A1 | Use of Pl3K Inhibitors for the Treatment of Obesity, Steatosis and Ageing | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-06-05 | — | — | US | disclosed |
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140154232-A1 | Use of Pl3K Inhibitors for the Treatment of Obesity, Steatosis and Ageing | PLIN1, PCK2, PLIN3 | CYP2D6 4437/4885USP2 1248/4885SMN1; SMN2 4588/4885 |
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | MTOR, PIK3CA, PI4KA | CYP2D6 1969/4885USP2 3475/4885SMN1; SMN2 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.